Objective In a primary care population covering a broad spectrum of cardiovascular risk (HIPPOCRATES project) the relationship between carotid intima-media thickness (CIMT) and six cardiovascular polymorphisms were analyzed in a cross-sectional study.
Introduction
Carotid intima-media thickness (CIMT) is often increased in patients with cardiovascular risk factors, such as hypertension, diabetes mellitus and hypercholesterolemia [1, 2] . It has also been suggested that an increased CIMT is an independent predictor of future myocardial infarction, stroke and peripheral artery disease [1] [2] [3] . Consequently, CIMT is regarded as a surrogate marker for preclinical atherosclerosis [1, 4] . Current research has shown that CIMT is not only associated with traditional cardiovascular risk factors, but also with certain genetic variants. Among the many potential genes, those related to activation of the renin-angiotensin system (RAS) or to an increased tendency to retain sodium rank high, and so do genes which may cause reduced availability of nitric oxide [5, 6] . Indeed, some studies suggest that certain genetic polymorphisms of the RAS may be important modifiers of CIMT [7, 8] . Most of these observations, however, have been obtained in selected populations and this prompted us to address such associations in a primary care population. Based on the literature available at the start of the project, we restricted ourselves to the analysis of only six polymorphisms. These were the angiotensinogen [AGT (M235T)], angiotensin-converting enzyme [ACE (4656 rpt )] and the angiotensin II type 1 receptor [AGTR1 (A1166C)] polymorphism, because these genes are involved in the generation and action of angiotensin II (Ang II) [9] [10] [11] . In addition, we assessed the role of polymorphisms which may be related to an enhanced reabsorption of sodium, that is the G-protein b3 subunit [GNB3 (C825T)] and a-adducin [ADD1 (G460W)] polymorphism [12, 13] . Finally, we looked at the endothelial nitric oxide synthase [NOS3 (E298D)] polymorphism because this may be associated with altered nitric oxide availability [14] . We hypothesized that the presence of one or more mutant alleles of the aforementioned polymorphisms would affect CIMT values. Therefore, in the present study, we aimed to assess the association of these six polymorphisms with CIMT.
Methods

Study population
For this study, we used data from the HIPPOCRATES project. The HIPPOCRATES project (Hypertension: Interaction and Prevalence of POlymorphisms related to Cardiovascular Risk and the Association to Treatment Efficacy Study) is an ongoing study, in which the implementation of genetic polymorphisms in the assessment of cardiovascular risk in primary care is investigated [15] [16] [17] . All participants for this project were recruited from one general practice in Kerkrade, the Netherlands, between May 2003 and July 2005. This academic general practice takes part in the Registration Network Family Practices, which is a continuous and computerized database. All relevant health problems, including a full medical history of all cardiovascular events have been registered since 1990 [18] . Medical problems are coded according to the International Classification of Primary Care (ICPC) using the criteria of the International Classification of Health Problems in Primary Care for diagnoses [19, 20] . The general practice in Kerkrade has a list of approximately 4400 patients, among whom more than 2300 patients are 40 years and older. The practice is located in a region with a high burden of cardiovascular disease and cardiovascular risk factors and, therefore, it has well implemented cardiovascular consulting hours. For the HIPPOCRATES project, all known patients aged 40 years or more with cardiovascular disease and hypertension were invited. From the group with cardiovascular risk factors other than hypertension, such as smoking, alcohol, diabetes mellitus, hypercholesterolemia, overweight including obesity, a random 1 : 3 sample was taken. Of all patients without known cardiovascular disease, hypertension or other cardiovascular risk factors, also a random 1 : 3 sample was taken. Classification was validated by thorough analysis of the patients' records combined with additional measurements of risk factors for all participants. The total HIPPOCRATES population consisted of 803 patients (382 men, 421 women). During their first visit, participants were asked permission to measure their CIMT. Included participants did not differ in baseline characteristics from those who did not consent (185 participants). CIMT was measured successfully in all 618 participants: 289 men and 329 women. These were included in the present study. The study was approved by the Medical Ethics Committee of the University Hospital Maastricht. All patients gave written informed consent to participate in the study.
Clinical data collection
All clinical measurements were performed in the practice by one of the authors (A.P.; first measurement) and a nurse practitioner (second, third and fourth measurements with in between periods of 3 months). The nurse practitioner measured weight, blood pressure and heart rate. All persons were questioned on their smoking behavior and alcohol consumption. Weight and height of all participants were measured. BMI was calculated as body weight divided by squared height. The size of the waist circumference was measured. Blood pressure and heart rate were measured after 10 min rest in sitting position, using a sphygmomanometer. Fasting blood samples were drawn to determine serum creatinine, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, serum triglycerides and glucose levels and analyzed in one regional laboratory. Microalbuminuria was determined semiquantitatively in a first morning urine sample.
Treatment status
The computerized medication lists were analyzed for antihypertensive, hypolipidemic, antiplatelet and antidiabetic medication. Furthermore, all persons were questioned about their medication use at the start of the study. Cardiovascular medication was based on the anatomical therapeutic classification (ATC) and defined as having at least one prescription of antihypertensive (ATC level 2: C02, C03, C04, C07, C08, C09), hypolipidemic (ATC level 2: C10) or antiplatelet (ATC level 5: B01AC) medication in the selected study period. This definition was chosen because these drugs are most frequently prescribed for the prevention of cardiovascular disease in primary care. Combination therapy was defined as having at least two different prescriptions of antihypertensive, hypolipidemic or antiplatelet medication used concomitantly during the study period. Antidiabetic medication was defined as having at least one prescription of A10 (ATC level 2) in the study period.
Definitions
Hypertension was defined as a SBP 140 mmHg or more and/or DBP 90 mmHg or more according to the Guidelines for Hypertension specified by the European Society of Hypertension [21] . Mean arterial pressure (MAP) was calculated as MAP ¼ (2 Â DBP þ SBP)/3. Dyslipidemia was considered to be present when the total cholesterol to HDL cholesterol ratio exceeded 4.0. Diabetes mellitus was considered to be present in case of fasting plasma glucose levels higher than 6.9 mmol/l. Creatinine clearance was calculated by the Cockcroft-Gault formula. Microalbuminuria was defined as albumin excretion above 20 mg/l.
Carotid intima-media thickness CIMT measurements were performed by one of the authors (A.P.) at the Circulation Laboratory of the Department of Internal Medicine of the University Hospital Maastricht. To measure CIMT, high-resolution B-mode ultrasonography was performed with ESAOTE PICUS 3 equipped with a 7.5-MHz linear array transducer. The left and right common carotid arteries were examined in anterolateral, posterolateral and medialateral directions. Measurements were performed 1 cm proximal to the beginning of the dilatation of the carotid bulb. The mean CIMT of the far wall of the common carotid artery was measured automatically over 1 cm, during seven heart beats and was accepted as correct as the mean SD less than 0.05, according to the Mannheim Carotid IntimaMedia Thickness Consensus [1] . In order to correct for asymmetry of the arterial vessel and to enhance reproducibility, CIMT was measured at four different angles and mean values were calculated for both the left and the right carotid artery. The internal diameter of the carotid artery was defined as the distance between the media-adventitia interfaces of the near and far arterial wall. Carotid atheromatous plaques were defined as focal structures encroaching into the arterial lumen and where its thickness was at least 50% greater than that of the adjacent sites [1] . For this article, plaques were not analyzed. [22] . Briefly, in the first stage, a multiplex PCR is carried out to amplify the gene fragments that contain the polymorphisms. In the second stage, the polymorphic positions are interrogated by a SBE reaction using fluorescently labeled ddNTPs. The oligos used for the SBE have specific lengths, varying from 22 to 50 nt. After the SBE assay, the fragments are size-resolved on an ABI3100 Genetic Analyser: the size of the peaks identifies the locus (e.g. ADD1) and the color of the peak(s) identifies the genotype (e.g. Gly/Trp). Raw data were analyzed with Genescan Analysis software (version 3.7), then genotypes were scored independently by two researchers and entered in the database. In 27 patients, a second analysis was necessary to obtain all the genotypes. The ACE (I/D) polymorphism was determined by detecting ACE 4656þCT observed on the SNaPshot as ACE (4656 rpt ). The use of this SNaPshot method does not allow the direct determination of the insertion/deletion polymorphism. The ACE 4656þCT polymorphism in the 3 0 -untranslated region of the ACE gene consists of a repetition of two or three CT dinucleotides and is in complete linkage disequilibrium with ACE (I/D) [23, 24] . The multiplex assay was validated on a set of 100 DNA samples that had previously been genotyped with an alternative technique; this technique concerned a multilocus genotyping assay for candidate markers of cardiovascular disease risk (Roche Molecular Systems Inc., Pleasanton, California, USA) and has been described in detail previously [25] . Only four samples gave a discordant result for the NOS3 polymorphism. All other genotypes were concordant. The discordant results have been adjusted.
Genetic analyses
Statistical analysis
Statistical analysis was performed using SPSS statistical software, version 13.0 (SPSS Inc., Chicago, Illinois, USA). A P value of 0.05 or less was considered statistically significant. Statistical significance for differences in quantitative variables was tested by Student's t-test or MannWhitney U-test when appropriate. In case of categorical variables, the x 2 -test was used. Overall mean CIMT values were calculated by taking the average of the left and right mean CIMT values. Correction for sex differences in arterial diameter was provided by calculation of the CIMT/internal carotid diameter ratio. As we expected potential differences between men and women, we analyzed the data with respect to sex separately.
A power calculation indicated that the HIPPOCRATES population was large enough to calculate differences between groups. Assuming allele frequencies ranging between 0.51 and 0.79, a total group number of 590-635 would be sufficient to detect a clinical significant difference in CIMT of 0.035 mm with a power of 80% (a ¼ 0.05). Genotype and actual allele frequencies were calculated to test the Hardy-Weinberg equilibrium. Furthermore, allele frequencies were analyzed using x 2 -tests. Differences in frequency between groups larger than 0.04 were tested for significance. Significant covariables for the relationship between CIMT and polymorphisms were traced by multivariate linear regression analysis using backward model selection. To avoid collinearity, waist circumference was used instead of waistto-hip ratio or BMI and condensed measures were used like diabetes and dyslipidemia as defined earlier. Recent research has shown that waist circumference is a better marker of abdominal fat accumulation than waist-to-hip ratio or BMI [26] , which is strongly associated with increased cardiovascular risk [27] . MAP was used because it is constant along the arterial tree and hence reflects accurately the impact of pressure on the carotid segments. P values for co-variables to stay in the model were set at 0.10. Because of the skewed distribution of CIMT, log transformation was applied to achieve normality for further analysis. The contribution of all covariables to CIMT was calculated as the estimated effect on population mean CIMT. Univariate and multivariate linear regression analyses were performed to evaluate the relationship between polymorphisms and CIMT. For that purpose, the homozygous wild-type genotype was used as reference category. Age and sex, both demographic variables, were incorporated in both the univariate as well as the multivariate linear regression analyses. As indicated, we selected participants from different groups. In the regression analyses, we adjusted for this selection by creating dummy variables using the normotensive group without cardiovascular risk factors as the reference category. Adjustment for potential confounders was performed by incorporating age, sex, waist circumference, dyslipidemia and use of cardiovascular medication into the model (enter procedure) used for multivariate analysis. The simultaneous contribution of the six polymorphisms to the prediction of increased CIMT was determined, using the overall F-test. If two or more polymorphisms reached statistical significance, interactions (effect modification) between these polymorphisms with respect to CIMT were assessed. Again linear regression analysis (method: enter) was used, in which the alleles at risk, the interaction term between the alleles and the other covariates were incorporated. If an interaction became statistically significant, the model was explored further.
Results
Characteristics of the participants Baseline characteristics of the study population are summarized in Table 1 . There were slightly more women (53.2%) than men (46.8%) of whom 52.3% were treated with cardiovascular medication. Men more often had a history of ischemic heart disease, used more antiplatelet and hypolipidemic medication as compared to women. Additionally, they more often used alcohol, had a larger waist circumference and a lower HDL cholesterol. Their creatinine clearance was higher as compared with women and more often had microalbuminuria. Overall, the observed values in CIMT between men and women (Table 2) were not significantly different, except for the age category 50-59 (P ¼ 0.023) (see also Fig. 1) . However, women have a higher CIMT-to-diameter ratio than men, because the internal diameter of their carotid artery is smaller ( Table 2) .
Allele frequencies
Genotype and allele frequencies of all polymorphisms were in Hardy-Weinberg equilibrium. No differences in allele frequencies were found between men and women, except for NOS3 (P ¼ 0.01). For this polymorphism, women had a higher frequency of the T-allele (Table 3) .
Intima-media thickness and cardiovascular polymorphisms
Stepwise regression analysis identified age, sex, waist circumference, dyslipidemia and use of cardiovascular medication as significant co-variables for the association between the six polymorphisms and CIMT (Table 4 ). In the univariate linear regression analyses, an association was found between CIMT and carriers of the T-allele of ADD1. This association was statistically significant for the overall group ( Fig. 2a , P ¼ 0.01), but when men and women were analyzed separately, only in women statistical significance was reached (P ¼ 0.02) with or without correction for internal carotid diameter. After correction for all covariates using multivariate linear regression analyses (Table 5) , we assessed for the overall group an independent significant relationship between CIMT and ADD1 (P ¼ 0.01). However, the simultaneous contribution of all six polymorphisms to the change in CIMT (overall F-test) was not statistically significant, except for women (P ¼ 0.04), due to a statistically significant harmful association for carriers of the C-allele of AGTR1 (P ¼ 0.03) and a protective association for carriers of the T-allele of ADD1 (P ¼ 0.03). For all other polymorphisms, carriers of the rare allele were not statistically significant associated with CIMT. Furthermore, there were no other statistically significant differences for these associations between men and women (Table 5) . For women, a multivariate posthoc evaluation of possible interactions between presence of the C-allele of AGTR1 and homozygosity of the G-allele of ADD1 showed overall an increase of 36 mm in CIMT [36.6 (À6.2 to 76.2)]. This interaction was of borderline statistical significance (P ¼ 0.09). The CIMT in women with both C Ã /GG was statistically significant thicker than in women with both AA/T Ã (P ¼ 0.04, Fig. 2b ).
Discussion
To the best of our knowledge, this is the first study on CIMT and cardiovascular polymorphisms in a primary care population reflecting current daily practice. Variables that were significantly associated with CIMT were age, sex, waist circumference, dyslipidemia and use of cardiovascular medication, which was in accordance with previous findings [2, 28] . In multivariate linear regression analyses, a statistically significant harmful association of the C-allele of AGTR1 with CIMT was found for women only (P ¼ 0.03). For the T-allele of ADD1, a protective association was found in men and women, but statistical significance was only reached in women (P ¼ 0.03). Posthoc analyses revealed a potential synergism between AGTR1 and ADD1 in relation to CIMT (Fig. 2b) . c The distance between the media-adventitia interfaces of the near and far arterial wall. 
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Carotid intima-media thickness (CIMT; mm) versus age categories (years) for men (n ¼ 289) and women (n ¼ 329) (P ¼ 0.342). Values are means AE standard error.
Carotid intima-media thickness and sex differences
In most studies, male sex is associated with increased CIMT [2, 29, 30] . Women have most often the thinnest CIMT [2, 29, 30] . For the CIMT-to-internal carotid diameter ratio, the same kind of results are observed, although this ratio yields the weakest associations with, for instance, acute myocardial infarction [31] . Our study results are not in line with these findings, especially if we look at CIMT values corrected for differences in arterial diameter (Table 2) . A possible explanation might be that men are treated more than women with cardiovascular risk-reducing therapies (Table 1) .
Angiotensin II type I receptor (A1166C) polymorphism
The observed association between carriers of the rare Callele of AGTR1 and higher CIMT has been reported by other authors [32, 33] , although many other investigators failed to find any significant relation. The mechanism for this association remains unclear, because the AGTR1 polymorphisms are located in the 3 0 -untranslated region (3 0 -UTR) of the chromosome 3q22 [34] and, therefore, the amino-acid sequence of the receptor is not altered. However, recently, the 3 0 -UTR site has been shown to be involved in microRNA gene silencing [35] . MicroRNAs are single-stranded RNA molecules of about 21-23 nucleotides in length, which regulate gene expression. They are processed from primary transcripts and their main function is to downregulate gene expression (gene silencing). The C-allele carriers have impaired micro-RNA binding and a consequent impairment of translation attenuation, resulting in increased receptor density [35] . Such AGTR1 receptor alterations have a number of possible effects that may influence CIMT, including increased extracellular matrix (ECM) formation, smooth muscle cell (SMC) migration, oxidation of LDL and the formation of reactive oxygen species (ROS), eventually initiating the inflammation process in the vascular cells [36] . Previously, we have shown that there is also an increase in angiotensin II sensitivity [37] . So, these mechanisms might explain the observed higher CIMT for C-allele cariers of the AGTR1 polymorphism. Evidence for sex differences with respect to these mechanisms was not present in the literature. a-Adducin (G460W) polymorphism Several studies have reported an association between ADD1 (G460W) polymorphism, salt sensitivity or high sodium intake and an increased risk of cardiovascular events and mortality [38, 39] . Moreover, the risk of cardiovascular events and mortality was shown to be increased in T-allele carriers with high SBP [40] . Recently, in the Rotterdam study and in another study in young adult men performed by Sarzani et al. [41] , an increased CIMT was found for carriers of the T-allele [42] . Balkestein et al. [43] found that the T-allele of ADD1 was associated with Table 4 Relevant co-variables for the association between carotid intima-media thickness and six cardiovascular polymorphisms Results of multivariate linear regression analysis using backward model selection in 618 participants. CI, 95% confidence interval; CIMT, carotid intima-media thickness; MAP, mean arterial pressure. a Population mean is 684.23 mm. b Men were coded as 0 and women as 1.
c Variables were coded 0 or 1 if the condition was absent or present.
# P 0.05. increased femoral artery IMT, but only in the context of the ACE DD genotype. The results of our study are not in line with these findings, that is female carriers of the T-allele are associated with a lower CIMT, indicating that they are at lower risk for developing CVD in comparison with women with the GG genotype. Additionally, compared with men, women carriers of the T-allele have a significantly lower risk to develop CVD, although we realize that in the overall analysis correction for sex yielded an overall protective association for T-allele carriers. A possible explanation may be related to the treatment status of the participants. Previously, it has been reported that there is an interaction between carriers of the rare T-allele of ADD1 and diuretic therapy [44] . Hypertensive participants carrying the rare T-allele, who were treated with diuretics, were at lower risk of myocardial infarction and stroke compared with participants treated with other antihypertensive therapies. We checked our database for the use of diuretics and found no association with diuretics. So, although attractive, the concurrent use of diuretics does not explain our findings. Another explanation might be the use of combination therapy, which may modify the behavior of the CIMT. We also checked whether carriers of the T-allele of the ADD1 polymorphism more often used combination therapies and found no association with combination therapy. Additionally, we analyzed the data only in patients without treatment. Again the same results were observed, although not statistically significant (P ¼ 0.20), probably due to the small number of patients available for such an analysis. Our finding of a protective association with outcome for the rare allele of ADD1 is, however, not an isolated unique observation. Tobin, et al. [45] also found such a protective association for ADD1 in a multilocus case-control study in which patients with myocardial infarction were compared with healthy controls. They suggested that this protective effect is likely to be through a cellular mechanism different from its effect leading to hypertension. Other authors also indicated that the duration of treatment with medication reduces the increase in CIMT [46, 47] . This may in our study indeed be an alternative explanation for the observed protective effect of the T-allele of ADD1. Carriers of the rare T-allele for the ADD1 (G460W) polymorphism are probably treated at earlier age and, consequently, longer with medication leading to reduced CIMT [48] . We checked our database for treatment duration and found no statistically significant difference in treatment duration between carriers of the normal (GG) and rare Tallele of the ADD1 (G460W) polymorphism. However, we realize that our design is cross-sectional. This implicates two major problems. First, CIMT is influenced by cardiovascular medication, and second, channeling plays an important role, that is the most severe cardiovascular patients are treated more intensively. In a cross-sectional design, the contribution of these two factors cannot be distinguished and, therefore, we think duration of treatment needs to be evaluated in future prospective studies.
Endothelial nitric oxide synthase (E298D) polymorphism Although we found a statistically significant higher frequency of the rare T-allele for the NOS3 (E298D) polymorphism in women, our multivariate linear regression analyses indicated that NOS3 did not contribute to higher CIMT. Homozygosity of the rare T-allele of NOS3 has been shown to be associated with coronary heart disease, carotid atherosclerosis and endothelial function [49] . Recent studies found statistically significant associations between increased CIMT and NOS3. In additional analyses for NOS3, both univariate and multivariate, for homozygosity of the rare allele, we could not confirm these findings, although the allele frequency of the rare T-allele in our population was similar or higher as compared with that in other studies [50, 51] .
Strengths and limitations
Several limitations of our study need to be discussed. and right CIMT values separately, this did not alter our results. Fourth, for reasons of comparability, we analyzed mean CIMT values, although the sex differences in CIMT values only were statistically significant when they were corrected for sex differences in internal carotid diameter, except for the age category 50-59. Analyses using CIMTto-diameter ratio did not alter our results. Thus far, only a few studies have explored the CIMT-to-diameter ratio, although they did report on sex differences [31, 53] . Other studies have shown that the cross-sectional area of IMT (CSA-IMT) is also an important correction for measurements of CIMT. However, analyses using the CSA-IMT did again not alter our results. Fifth, one could argue that we did not correct for multiple testing. We had, however, a clear a priori hypothesis, which limited the number of hypotheses tested. Finally, as is for many genetic association studies, a limitation of the present study is sample size [54] . Therefore, as stated by Ginsburg et al. [55] , these findings should be replicated in at least one independent cohort. However, at the start of our study in 2002, such a confirmation cohort was not included.
Recently, it has been shown that CIMT is an important surrogate marker of atherosclerosis in the clinical trial setting [56] . Therefore, we think the results of our study are of utmost importance, because our results reflect the use of CIMT in daily practice and not the controlled setting of a clinical trial. Therefore, we were able to assess the influence on CIMT of several factors, including the six polymorphisms. Furthermore, we used a relatively unselected population from primary care, in which the whole spectrum of cardiovascular risk was present and well defined. From the perspective of prevention this is clinically relevant, because the general practitioner is first responsible for the long-term cardiovascular risk management of his patients. Furthermore, results from studies among unselected populations may lead to better cardiovascular risk stratification, not only for the index patient, but possibly for (first degree) family members as well. Eventually, it might offer opportunities for genetically tailored treatment.
In conclusion, this study in a primary care population showed statistically significant associations between AGTR1 and CIMT in women and between ADD1 and CIMT for both men and women, but only statistically significant in women. The observed protective association of the T-allele of ADD1 with CIMT under pharmacological therapy warrants further study on the role of this polymorphism. Our findings should be viewed as hypothesis-generating and require further confirmation in prospective epidemiological primary care studies.
